Harmony Biosciences (HRMY) Tops Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
August 1, 2023 7:30 AM EDTWAKIX® (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023
Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter 2023
Exited Second Quarter 2023 With ~5,600 Patients on WAKIX
Completed Enrollment in Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study; On-track for Topline Data in Fourth Quarter 2023
Plans to Initiate Prader-Willi Syndrome (PWS) Phase 3 Study in Fourth Quarter 2023
Board of Directors Authorized $125 Million Share Repurchase Program
Conference Call... More
